2026-07-17
25 分钟This is In Conversation from Apple News.
I'm David Green in for Shamita Besu.
Today, the GLP-1 experiment happening in real time.
Millions of people in the U.S.
Are taking GLP-1 medications right now, an estimated one in eight adults.
You probably know these drugs by their brand names, Ozempic, Wagovi, Manjaro, and Zepbound, just to name a few.
GLP-1-based drugs have been around for years and were originally intended for treating diabetes, but they exploded
in use when researchers discovered they could cause significant weight loss and were approved for treating obesity.
But people are now reporting improvements across a remarkably wide range of other conditions as well,
from addiction to concussion symptoms to fertility, most of which have yet to be formally studied.
The landscape is changing so fast.
There's new drugs coming on all the time.
And we're learning in real time what these drugs are doing.
That is Julia Baluz.
She's a contributing opinion writer to the New York Times and co-author of the book Food Intelligence,
the Science of How Food Both Nourishes and Harms Us.
Julia has been reporting on GLP-1s for years,
so I wanted to have her on the show to take stock of this moment.
What has changed since these drugs became a cultural phenomenon?
What the evidence shows and still cannot answer?